CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 188 participants.
Also called NCT06304857
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 188 participants
- Sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
- Registry
-
NCT06304857
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT06304857. Randomized; quadruple masking; primary purpose prevention. Start 2024-04-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
- Acronym
- PROTECTAA
- Condition
- Breast Cancer
- Condition
- Heart Failure
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- 4th Military Clinical Hospital with Polyclinic, Poland
Record details
- Record id
cardio:ct-nct06304857- Content hash
5cad54fb3d636c0efaf2b14ac7321967081e6e4773390bc56b5bfcf44c9db070